Hepatitis C Virus Infection Associated With Administration of Intravenous Immune Globulin
作者： Joseph S. Bresee
DOI: 10.1001/JAMA.1996.03540190035026
关键词:
摘要: Objective. —To determine the risk of and factors for hepatitis C virus (HCV) infection among persons with immune deficiencies who had received intravenous globulin (IGIV) between March 1993 February 1994. Design. —Retrospective cohort study. Setting. —An immunology program in a tertiary care hospital. Patients. —Of 341 IGIV 1,1993, 22,1994, 278 (82%) were enrolled. The mean age enrolled was 9 years, 99% primary deficiencies. Main Outcome Measures. —Evidence HCV by detection sera antibody to and/or RNA reverse transcriptase polymerase chain reaction. Results. —Twenty-three (11%) 210 Gammagard (Baxter Healthcare Corporation, Deerfield, III) became infected compared none 52 exclusively other products (P=.01). In multivariate analysis, associated only produced from plasma screened second-generation (multiantigen) anti-HCV tests (P=.03). Hepatitis detected Gammagard, transmission recipients increased increasing quantity infused, 0 those no RNA-positive lots 29% quartile patients receiving greatest amount (P Conclusion. —Gammagard product implicated HCV. Infection higher quantities anti-HCV-screened plasma. Further studies are needed reasons infectivity viral inactivation removal steps ensure safety products.
sci-hub.se 参考文章(15)
Paul Martin, Adrian M. Di Bisceglie, Chris Kassianides, Mauricio Lisker-Melman, Jay H. Hoofnagle, Rapidly progressive non-A, non-B hepatitis in patients with human immunodeficiency virus infection Gastroenterology. ,vol. 97, pp. 1559- 1561 ,(1989) , 10.1016/0016-5085(89)90405-8
D S Vallari, B W Jett, H J Alter, L T Mimms, R Holzman, J W Shih, Serological markers of posttransfusion hepatitis C viral infection. Journal of Clinical Microbiology. ,vol. 30, pp. 552- 556 ,(1992) , 10.1128/JCM.30.3.552-556.1992
J.S. Finlayson, DonaldL. Tankersley, Anti-HCV screening and plasma fractionation: the case against. The Lancet. ,vol. 335, pp. 1274- 1275 ,(1990) , 10.1016/0140-6736(90)91335-8
Anna SF Lok, David Chien, Qui-Lim Choo, Tak-Mao Chan, Edmond KW Chiu, Ignatius KP Cheng, Michael Houghton, George Kuo, None, Antibody response to core, envelope and nonstructural hepatitis C virus antigens : comparison of immunocompetent and immunosuppressed patients Hepatology. ,vol. 18, pp. 497- 502 ,(1993) , 10.1002/HEP.1840180305
P. Marcellin, M. Martinot-Peignoux, A. Elias, M. Branger, F. Courtois, R. Level, S. Erlinger, J. P. Benhamou, Hepatitis C Virus (HCV) Viremia in Human Immunodeficiency VirusSeronegative and -Seropositive Patients with Indeterminate HCV Recombinant Immunoblot Assay The Journal of Infectious Diseases. ,vol. 170, pp. 433- 435 ,(1994) , 10.1093/INFDIS/170.2.433
Janne Björkander, Charlotte Cunningham-Rundles, Per Lundin, Rolf Olsson, Ruzena Söderström, Lars Å. Hanson, Intravenous immunoglobulin prophylaxis causing liver damage in 16 of 77 patients with hypogammaglobulinemia or IgG subclass deficiency. The American Journal of Medicine. ,vol. 84, pp. 107- 111 ,(1988) , 10.1016/0002-9343(88)90016-2
RM Biswas, S Nedjar, LT Wilson, FD Mitchell, PJ Snoy, JS Finlayson, DL Tankersley, The effect on the safety of intravenous immunoglobulin of testing plasma for antibody to hepatitis C Transfusion. ,vol. 34, pp. 100- 104 ,(1994) , 10.1046/J.1537-2995.1994.34294143934.X
M.W. Yu, B.L. Mason, Z.P. Guo, D.L. Tankersley, S. Nedjar, F.D. Mitchell, R.M. Biswas, C.M. Nübling, H. Willkommen, J. Lower, Hepatitis C transmission associated with intravenous immunoglobulins. The Lancet. ,vol. 345, pp. 1173- 1174 ,(1995) , 10.1016/S0140-6736(95)91002-6
MY Yu, BL Mason, DL Tankersley, Detection and characterization of hepatitis C virus RNA in immune globulins. Transfusion. ,vol. 34, pp. 596- 602 ,(1994) , 10.1046/J.1537-2995.1994.34794330014.X
R.S Lane, Non-A, non-B hepatitis from intravenous immunoglobulin. The Lancet. ,vol. 322, pp. 974- 975 ,(1983) , 10.1016/S0140-6736(83)90496-8